<DOC>
	<DOCNO>NCT02572245</DOCNO>
	<brief_summary>This study compare adalimumab Pfizer ( PF-06410293 ) administer subcutaneous ( SC ) injection use pre-filled syringe ( PFS ) pre-filled pen healthy adult subject</brief_summary>
	<brief_title>A Study PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Healthy female subject and/or male subject , , time screening , age 18 55 year , inclusive . Healthy define clinically relevant abnormality identify detailed medical history , complete physical examination include blood pressure pulse rate measurement , 12 lead electrocardiogram ( ECG ) , clinical laboratory test . 2 . Body Mass Index ( BMI ) 17.5 32 kg/m2 ; total body weight &gt; 50 kg ( 110 pound ) . 3 . Chest X ray evidence current , active TB previous ( inactive ) TB , fungal general infection , heart failure , malignancy , clinically significant abnormality take Screening within 24 week prior Day 1 read qualify radiologist . 4 . Female subject non childbearing potential must meet least one follow criterion : . Achieved postmenopausal status , define follow : cessation regular menses least 12 consecutive month alternative pathological physiological cause ; status may confirm serum follicle stimulate hormone ( FSH ) level confirm post menopausal state ; b . Have undergone document hysterectomy and/or bilateral oophorectomy ; c. Have medically confirm ovarian failure . All female subject ( include female tubal ligation ) consider childbearing potential . 1 . Evidence history clinically significant infectious , hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , autoimmune , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . 2 . Evidence history nervous system demyelinate disease ( include multiple sclerosis , optic neuritis , Guillain Barr√© syndrome ) . 3 . History relevant orthostatic hypotension , faint spell blackout . 4 . Previous history cancer , except adequately treat basal cell squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Healthy Subjects</keyword>
	<keyword>Device</keyword>
	<keyword>PK</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Single Dose</keyword>
</DOC>